Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)
dc.contributor.author | Tewari, Krishnansu S. | |
dc.contributor.author | Sill, Michael W. | |
dc.contributor.author | Monk, Bradley J. | |
dc.contributor.author | Penson, Richard T. | |
dc.contributor.author | Moore, David H. | |
dc.contributor.author | Lankes, Heather A. | |
dc.contributor.author | Ramondetta, Lois M. | |
dc.contributor.author | Landrum, Lisa M. | |
dc.contributor.author | Randall, Leslie M. | |
dc.contributor.author | Oaknin, Ana | |
dc.contributor.author | Leitao, Mario M. | |
dc.contributor.author | Eisenhauer, Eric L. | |
dc.contributor.author | DiSilvestro, Paul | |
dc.contributor.author | Le, Linda Van | |
dc.contributor.author | Pearl, Michael L. | |
dc.contributor.author | Burke, James J. | |
dc.contributor.author | Salani, Ritu | |
dc.contributor.author | Richardson, Debra L. | |
dc.contributor.author | Michael, Helen E. | |
dc.contributor.author | Kindelberger, David W. | |
dc.contributor.author | Birrer, Michael J. | |
dc.contributor.department | Pathology and Laboratory Medicine, School of Medicine | en_US |
dc.date.accessioned | 2023-03-03T15:05:34Z | |
dc.date.available | 2023-03-03T15:05:34Z | |
dc.date.issued | 2020-11 | |
dc.description.abstract | To isolate circulating tumor cells (CTCs) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival (OS) and progression-free survival (PFS). 7.5 mL of whole blood was drawn pre-cycle 1 and 36 days post-cycle 1 from patients enrolled on Gynecologic Oncology Group 0240, the phase III randomized trial that led directly to regulatory approval of the anti-angiogenesis drug, bevacizumab, in women with recurrent/metastatic cervical cancer. CTCs (defined as anti-cytokeratin positive/anti-CD45 negative cells) were isolated from the buffy coat layer using an anti-EpCAM antibody-conjugated ferrofluid and rare earth magnet, and counted using a semi-automated fluorescence microscope. The median pre-cycle 1 CTC count was 7 CTCs/7.5 mL whole blood (range, 0–18) and, at 36 days post-treatment, was 4 (range, 0–17). The greater the declination in CTCs between time points studied, the lower the risk of death (HR 0.87; 95% CI, 0.79–0.95). Among patients with high (≥ median) pre-treatment CTCs, bevacizumab treatment was associated with a reduction in the hazard of death (HR 0.57; 95% CI, 0.32–1.03) and progression (PFS HR 0.59; 95% CI, 0.36–0.96). This effect was not observed with low (< median) CTCs. CTCs can be isolated from women with advanced cervical cancer and may have prognostic significance. A survival benefit conferred by bevacizumab among patients with high pre-treatment CTCs may reflect increased tumor neovascularization and concomitant vulnerability to VEGF inhibition. These data support studying CTC capture as a potential predictive biomarker. | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Tewari KS, Sill MW, Monk BJ, et al. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020;19(11):2363-2370. doi:10.1158/1535-7163.MCT-20-0276 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/31593 | |
dc.language.iso | en_US | en_US |
dc.publisher | American Association for Cancer Research | en_US |
dc.relation.isversionof | 10.1158/1535-7163.MCT-20-0276 | en_US |
dc.relation.journal | Molecular Cancer Therapeutics | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Cervical cancer | en_US |
dc.subject | Circulating tumor cells | en_US |
dc.subject | Angiogenesis | en_US |
dc.subject | Bevacizumab | en_US |
dc.title | Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062) | en_US |
dc.type | Article | en_US |